Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107321 | 0.93 | PPARG (0.59) | PPARGPTGER1 | |
| SCHEMBL5109103 | 0.90 | PPARG (0.54) | PPARGPTGER1 | |
| SCHEMBL5105830 | 0.88 | PPARG (0.52) | PPARGPTGER1 | |
| SCHEMBL5111995 | 0.83 | PPARG (0.51) | PPARGPTGER1 | |
| SCHEMBL3221332 | 0.81 | PPARG (0.52) | PPARGPTGER1 | |
| SCHEMBL5112174 | 0.81 | PPARG (0.56) | PPARG | |
| SCHEMBL5109712 | 0.79 | PPARG (0.45) | PPARGPTGER1 | |
| SCHEMBL5113434 | 0.79 | PPARG (0.55) | PPARG | |
| SCHEMBL5113860 | 0.77 | PPARG (0.52) | PPARG | |
| SCHEMBL5113115 | 0.77 | PPARG (0.46) | PPARGPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885PTGER1 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.